May 16 2017 - Allergan is pleased to announce the Health Canada approval of Viberzi (eluxadoline) for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. 

IBS-D patients suffer from frequent and urgent episodes of diarrhoea, abdominal pain, bloating and cramping, making it difficult for patients to manage work, family, and social life. Despite the significant impact on quality of life, patients often wait years before seeking medical help, relying on multiple prescription and over the counter medications with little success.

Read Allergan press release